Hikma Pharmaceuticals Plc Holding(s) in Company (4465V)
December 13 2013 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 4465V
Hikma Pharmaceuticals Plc
13 December 2013
Notification of Major Interests in Shares
LONDON, 13 December 2013 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the Hikma Pharmaceuticals
underlying issuer of existing PLC
shares to which the voting
rights are attached
------------------------------- ----------------------
2 Reason for the notification
----------------------------------- ----
An acquisition or disposal Yes
of voting rights
----------------------------------- ----
An acquisition or disposal No
of financial instruments which
may result in the acquisition
of shares already issues to
which voting rights are attached
----------------------------------- ----
An event changing the breakdown No
of voting rights
----------------------------------- ----
Other (please specify): Compliance No
with the Transparency Directive
----------------------------------- ----
3 Full name of the person subject Norges Bank
to the notification obligation
---------------------------------- -----------------
4 Full name of shareholders N/A
---------------------------------- -----------------
5 Date of the Transaction (and 11 December 2013
date on which the threshold
crossed is reached differently)
---------------------------------- -----------------
6 Date on which the issuer notified 12 December 2013
---------------------------------- -----------------
7 Threshold that is crossed Below 3%
---------------------------------- -----------------
8 Notified details (ABC)
-----------------------
A. Voting rights attached to shares
-----------------------------------------------------------------------------------------------------------
Class type Situation Resulting situation after the
of shares previous to triggering transaction
(if possible the triggering
using the transaction
ISIN code)
--------------- ------------------------ ----------------------------------------------------------------
Number Number Number of Number of % of voting
of shares of voting shares voting rights rights
rights
--------------- ----------- ----------- --------------------- --------------------- ------------------
Direct Indirect Direct Indirect Direct Indirect
--------------- ----------- ----------- ---------- --------- ---------- --------- ------- ---------
Ordinary
Shares
(0.10 GBP)
GB00B0LCW083 6,014,263 6,014,263 5,891,555 0 5,891,555 0 2.98% 0%
--------------- ----------- ----------- ---------- --------- ---------- --------- ------- ---------
B. Qualifying Financial instruments
---------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------
Type of Expiration Exercise/Conversion Number of % of voting
financial Date Period/Date voting rights rights
instrument that may be
acquired if
the instrument
if exercised/converted
------------ ----------- -------------------- ------------------------ ------------
- - - - -
------------ ----------- -------------------- ------------------------ ------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
---------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of % of voting
financial Price Date Period/Date voting rights rights
instrument instrument
refers to
------------ --------- ----------- -------------------- --------------- ----------------
Nominal Delta
------------ --------- ----------- -------------------- --------------- -------- ------
- - - - - - -
------------ --------- ----------- -------------------- --------------- -------- ------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
5,891,555 2.98%
------------------------ -------------------
9 Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable
----------------------------------------------------
N/A
----------------------------------------------------
Proxy Voting
-----------------------------------------------------
10 Name of the proxy holder Norges Bank
--- ---------------------------------- ------------
11 Number of voting rights proxy N/A
holder will cease to hold
--- ---------------------------------- ------------
12 Date on which proxy holder N/A
will cease to hold voting rights
--- ---------------------------------- ------------
13 Additional Information None
--- -------------------------- ---------------------
14 Contact name: Stanislav Boiadjiev,
Norges Bank
--- -------------------------- ---------------------
15 Contact telephone number: +47 24 07 3142
--- -------------------------- ---------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUUSBROAAUAAA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
